Drugs / Narazaciclib
Narazaciclib
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04739293 | May 2021 → Oct 2024 | — | Traws Pharma, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT05731934 | Sep 2020 → Jan 2024 | cancer | Hangzhou Hanx Biopharmaceuticals, Ltd. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06703255 | Jan 2025 → Dec 2026 expected | glioma | Hangzhou Hanx Biopharmaceuticals, Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06351644 | Oct 2024 → Apr 2025 | refractory plasma cell neoplasm | Adriana Rossi | Terminated | No outcome recorded |
| Phase 1/2 | NCT05705505 | Mar 2023 → Jan 2026 | endometrial endometrioid adenocarcinoma | Traws Pharma, Inc. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Narazaciclib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05705505 ↗ |
| Known as | HX301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06703255 ↗ |
| Known as | ON123300 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04739293 ↗ |
| Modality | Small molecule | — CHEMBL3115681 ↗ |
| Route | Oral | “Administered Orally as Escalating Daily Doses” NCT04739293 ↗ |